Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rallybio Corporation (RLYB)
:RLYB
Holding RLYB?
Track your performance easily
RLYB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.84 - $3.46
Previous CloseN/A
Volume36.64K
Average Volume (3M)101.94K
Market Cap
$36.92M
Enterprise Value-$22.73M
Total Cash (Recent Filing)$19.46M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Mar 18, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.59
Shares Outstanding41,487,587
10 Day Avg. Volume69,568
30 Day Avg. Volume101,944
Standard Deviation0.28
R-Squared0.07
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)60.72
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.62
Enterprise Value/Revenue-38.02
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.32
Forecast
1Y Price Target
$8.33Price Target Upside846.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Rallybio News
Bulls Say, Bears Say
Bulls Say
Manufacturing And Safety ImprovementsManufacturing enhancements have largely eliminated impurities that caused gastrointestinal adverse effects in earlier studies, improving the tolerability of RLYB116.
Regulatory ApprovalThe European Medicines Agency and the UK's Medicines and Healthcare products Regulatory Agency have approved Rallybio's clinical trial applications for a Phase 2 trial of RLYB212 in pregnant women.
Therapeutic AdvancementRLYB212 could become standard-of-care for fetal and neonatal alloimmune thrombocytopenia (FNAIT) given the lack of any FDA-approved therapy.
Bears Say
Clinical TrialsRisks include delays in clinical trials for pipeline candidates and failure to generate favorable clinical data, particularly for RLYB212 in FNAIT and RLYB116 in PNH.
Financial PerformanceAnalyst's recommendation includes lowering the 12-month target to $5 from the prior $6 per share after making operating expense adjustments.
Partnership RisksPartnership risk exists, specifically between Rallybio and companies like Swedish Orphan Biovitrum AB, Exscientia PLC, and Sanofi S.A.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RLYB FAQ
What was Rallybio Corporation’s price range in the past 12 months?
Rallybio Corporation lowest stock price was $0.84 and its highest was $3.46 in the past 12 months.
What is Rallybio Corporation’s market cap?
Rallybio Corporation’s market cap is $36.92M.
When is Rallybio Corporation’s upcoming earnings report date?
Rallybio Corporation’s upcoming earnings report date is Mar 18, 2025 which is in 56 days.
How were Rallybio Corporation’s earnings last quarter?
Rallybio Corporation released its earnings results on Nov 07, 2024. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.352 by $0.092.
Is Rallybio Corporation overvalued?
According to Wall Street analysts Rallybio Corporation’s price is currently Undervalued.
Does Rallybio Corporation pay dividends?
Rallybio Corporation does not currently pay dividends.
What is Rallybio Corporation’s EPS estimate?
Rallybio Corporation’s EPS estimate is -0.29.
How many shares outstanding does Rallybio Corporation have?
Rallybio Corporation has 41,487,587 shares outstanding.
What happened to Rallybio Corporation’s price movement after its last earnings report?
Rallybio Corporation reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.352. Following the earnings report the stock price went down -1%.
Which hedge fund is a major shareholder of Rallybio Corporation?
Currently, no hedge funds are holding shares in RLYB
---
Rallybio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.33 (846.59% Upside)
$8.33 (846.59% Upside)
Blogger Sentiment
Bearish
RLYB Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.2%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.14%
12-Months-Change
Fundamentals
Return on Equity
-68.90%
Trailing 12-Months
Asset Growth
-40.68%
Trailing 12-Months
Company Description
Rallybio Corporation
Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
---
RLYB Stock 12 Month Forecast
Average Price Target
$8.33
▲(846.59% Upside)
Technical Analysis
Seres Therapeutics
―
Fulcrum Therapeutics
―
Cabaletta Bio
―
Iovance Biotherapeutics
―
Sarepta Therapeutics
―
Viking Therapeutics
―
Best Analysts Covering RLYB
1 Year
1 Year Success Rate
1/28 ratings generated profit
1 Year Average Return
-49.63%
reiterated a buy rating 8 days ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 3.57% of your transactions generating a profit, with an average return of -49.63% per trade.
---